Biogen Inc. (BIIB) Stock

About Biogen Inc.

Biogen Inc. is led by CEO Christopher A. Viehbacher, employs 7,605 people, headquartered in Cambridge, US, publicly traded since 1991.

Biogen Inc. (BIIB) stock trades at $250.69 with a market capitalization of $37.04B. The stock is valued at a price-to-earnings (P/E) ratio of 40.07, price-to-book of 1.78, price-to-sales of 3.38. Over the past 52 weeks the stock has ranged between $135.39 and $253.84, and currently trades 1.2% below its 52-week high.

On profitability, Biogen Inc. generates a return on equity (ROE) of 4.52%, return on capital employed of 4.52%, an operating margin of 19.14%, a net profit margin of 8.39%.

In its most recent fiscal year, Biogen Inc. reported annual revenue of $9.8B, net profit of $1.3B. Over the last 5 fiscal years, revenue declined at an average annual rate of 6.1%, and net profit declined at an average annual rate of 20.2%.

The balance sheet shows a debt-to-equity ratio of 0.44 (debt below half of shareholders' equity), a current ratio of 2.68, total assets of $29.4B, $3.0B in cash and equivalents.

BIIB has an average daily trading volume of 1,141,196 shares, a beta of 0.17 (historically less volatile than the overall market).

Biogen Inc. by the numbers, 2016–2025

Between 2016 and 2025 Biogen Inc. reported revenue of $11.4B rising to $9.8B, a change of -14.3% across 10 years. Compounded, revenue has grown -6.1% a year over five years, -1.2% over three, 1.4% over the last twelve months. Net profit fell to $1.3B.

Operating margin went from 45.0% in 2016 to 19.1% in 2025, a fall of 25.9 percentage points. The most recent net margin is 8.39%. On a trailing twelve-month basis to Jun '26, revenue is $9.9B and net profit $837.0M.

Borrowings rose from $6.5B to $6.9B, cash from operations was $2.2B in the latest year, positive in 10 of the last 10.

Return on equity has averaged 12.3% over five years, and was 7.1% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Biogen Inc. (BIIB) — frequently asked questions